Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at earlier stages. Therefore, early detection of CRC has emerged as an important global issue to reduce its high mortality. Currently, colonoscopy is the most accurate screening method for early diagnosis of CRC. However, its compliance rate remains very low due to its invasiveness, dietary restriction requirement, and extensive bowel preparation. Although noninvasive fecal immunochemical tests (FIT) for hemoglobin in stool are available, their sensitivities are relatively low in detecting stage I CRC. Thus, developing highly accurate CRC screening method using molecular biomarkers for people who are reluctant to participate in colonoscopy examination is urgently needed for early detection of CRC.